View ValuationDocCheck 将来の成長Future 基準チェック /06現在、 DocCheckの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Healthcare Services 収益成長24.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesDeclared Dividend • May 20Dividend increased to €1.00Dividend of €1.00 is 33% higher than last year. Ex-date: 29th May 2026 Payment date: 2nd June 2026 Dividend yield will be 6.6%, which is higher than the industry average of 0.9%. Sustainability & Growth Dividend is not adequately covered by earnings (95% earnings payout ratio) nor is it covered by cash flows (227% cash payout ratio). The dividend has increased by an average of 9.6% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 5.7% to bring the payout ratio under control. However, EPS has declined by 11% over the last 5 years so the company would need to reverse this trend.お知らせ • Apr 17+ 1 more updateDocCheck AG, Annual General Meeting, May 28, 2026DocCheck AG, Annual General Meeting, May 28, 2026, at 09:30 W. Europe Standard Time.お知らせ • Apr 16+ 1 more updateDocCheck AG announces Annual dividend, payable on June 02, 2025DocCheck AG announced Annual dividend of EUR 0.7500 per share payable on June 02, 2025, ex-date on May 29, 2025 and record date on May 30, 2025.Valuation Update With 7 Day Price Move • Oct 01Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €8.40, the stock trades at a trailing P/E ratio of 17.6x. Average trailing P/E is 21x in the Healthcare Services industry in Europe. Total loss to shareholders of 59% over the past three years.Reported Earnings • Sep 26First half 2024 earnings released: EPS: €0.37 (vs €0.34 in 1H 2023)First half 2024 results: EPS: €0.37 (up from €0.34 in 1H 2023). Revenue: €24.4m (down 6.8% from 1H 2023). Net income: €1.87m (up 10% from 1H 2023). Profit margin: 7.7% (up from 6.5% in 1H 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings.New Risk • Sep 25New major risk - Revenue and earnings growthEarnings have declined by 4.3% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.3% per year over the past 5 years. Minor Risks Dividend is not well covered by earnings (104% payout ratio). Profit margins are more than 30% lower than last year (4.7% net profit margin). Market cap is less than US$100m (€37.8m market cap, or US$42.1m).Upcoming Dividend • May 23Upcoming dividend of €0.50 per shareEligible shareholders must have bought the stock before 30 May 2024. Payment date: 03 June 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 5.5%. Within top quartile of German dividend payers (4.6%). Higher than average of industry peers (1.6%).New Risk • Apr 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (€45.7m market cap, or US$48.6m).Reported Earnings • Oct 05First half 2023 earnings released: EPS: €0.34 (vs €0.42 in 1H 2022)First half 2023 results: EPS: €0.34 (down from €0.42 in 1H 2022). Revenue: €26.2m (down 11% from 1H 2022). Net income: €1.70m (down 19% from 1H 2022). Profit margin: 6.5% (down from 7.1% in 1H 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.New Risk • Jul 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (34% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (6.7% average weekly change). Market cap is less than US$100m (€53.4m market cap, or US$58.9m).Upcoming Dividend • May 25Upcoming dividend of €0.75 per share at 5.8% yieldEligible shareholders must have bought the stock before 01 June 2023. Payment date: 05 June 2023. Payout ratio is a comfortable 60% but the company is not cash flow positive. Trailing yield: 5.8%. Within top quartile of German dividend payers (4.7%). Higher than average of industry peers (1.7%).Valuation Update With 7 Day Price Move • May 22Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €13.50, the stock trades at a trailing P/E ratio of 10.5x. Average trailing P/E is 24x in the Healthcare Services industry in Germany. Total returns to shareholders of 52% over the past three years.Buying Opportunity • Nov 12Now 25% undervaluedOver the last 90 days, the stock is up 5.1%. The fair value is estimated to be €21.98, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 35% over the last 3 years. Earnings per share has grown by 39%.Valuation Update With 7 Day Price Move • Nov 05Investor sentiment improved over the past weekAfter last week's 19% share price gain to €14.80, the stock trades at a trailing P/E ratio of 6.7x. Average trailing P/E is 25x in the Healthcare Services industry in Germany. Total returns to shareholders of 76% over the past three years.Upcoming Dividend • May 25Upcoming dividend of €1.00 per shareEligible shareholders must have bought the stock before 01 June 2022. Payment date: 03 June 2022. Payout ratio is a comfortable 44% and this is well supported by cash flows. Trailing yield: 5.3%. Within top quartile of German dividend payers (4.3%). Higher than average of industry peers (1.3%).Buying Opportunity • May 21Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 28%. The fair value is estimated to be €22.93, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years. Earnings per share has grown by 61%.Reported Earnings • Apr 16Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: EPS: €2.27 (up from €1.83 in FY 2020). Revenue: €86.4m (up 37% from FY 2020). Net income: €11.4m (up 24% from FY 2020). Profit margin: 13% (down from 15% in FY 2020). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 100%. Earnings per share (EPS) exceeded analyst estimates by 65%. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has only increased by 37% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • May 24Upcoming dividend of €1.00 per shareEligible shareholders must have bought the stock before 31 May 2021. Payment date: 02 June 2021. Trailing yield: 3.6%. Within top quartile of German dividend payers (3.2%). Higher than average of industry peers (1.1%).Reported Earnings • Apr 18Full year 2020 earnings released: EPS €1.83 (vs €0.63 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €63.7m (up 97% from FY 2019). Net income: €9.20m (up 193% from FY 2019). Profit margin: 14% (up from 9.7% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Apr 07Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €23.80, the stock trades at a trailing P/E ratio of 28.1x. Average trailing P/E is 51x in the Healthcare Services industry in Germany. Total returns to shareholders of 151% over the past three years.Valuation Update With 7 Day Price Move • Feb 06Investor sentiment improved over the past weekAfter last week's 17% share price gain to €26.80, the stock is trading at a trailing P/E ratio of 31x, up from the previous P/E ratio of 26.6x. This compares to an average P/E of 42x in the Healthcare Services industry in Europe. Total returns to shareholders over the past three years are 183%.Is New 90 Day High Low • Feb 05New 90-day high: €26.00The company is up 53% from its price of €17.00 on 06 November 2020. The German market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 3.0% over the same period.Is New 90 Day High Low • Jan 07New 90-day high: €24.00The company is up 48% from its price of €16.20 on 09 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 5.0% over the same period.Valuation Update With 7 Day Price Move • Dec 21Investor sentiment improved over the past weekAfter last week's 16% share price gain to €23.60, the stock is trading at a trailing P/E ratio of 27.1x, up from the previous P/E ratio of 23.4x. This compares to an average P/E of 44x in the Healthcare Services industry in Europe. Total returns to shareholders over the past three years are 160%.Is New 90 Day High Low • Nov 11New 90-day high: €22.60The company is up 64% from its price of €13.80 on 13 August 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is flat over the same period.Valuation Update With 7 Day Price Move • Nov 11Market bids up stock over the past weekAfter last week's 35% share price gain to €22.60, the stock is trading at a trailing P/E ratio of 20x, up from the previous P/E ratio of 14.8x. This compares to an average P/E of 44x in the Healthcare Services industry in Europe. Total returns to shareholders over the past three years are 156%.Is New 90 Day High Low • Oct 08New 90-day high: €16.30The company is up 58% from its price of €10.30 on 10 July 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 8.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、DocCheck は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DB:AJ91 - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202555526N/A9/30/202556647N/A6/30/202556657N/A3/31/202555667N/A12/31/202454578N/A9/30/202453478N/A6/30/202452289N/A3/31/202453278N/A12/31/202353268N/A9/30/202355457N/A6/30/202358646N/A3/31/202359626N/A12/31/202261606N/A9/30/2022637-25N/A6/30/2022647-34N/A3/31/202275928N/A12/31/20218611711N/A9/30/202190121014N/A6/30/202193131417N/A3/31/202178111114N/A12/31/2020639812N/A9/30/202051758N/A6/30/202038435N/A3/31/202035424N/A12/31/201932312N/A9/30/2019313N/A3N/A6/30/2019303N/A3N/A3/31/2019293N/A4N/A12/31/2018282N/A4N/A9/30/2018292N/A3N/A6/30/2018292N/A3N/A3/31/2018282N/A3N/A12/31/2017282N/A3N/A9/30/2017283N/A3N/A6/30/2017273N/A3N/A3/31/2017263N/A3N/A12/31/2016263N/A3N/A9/30/2016263N/AN/AN/A6/30/2016273N/A3N/A3/31/2016273N/A3N/A12/31/2015273N/A4N/A9/30/2015252N/AN/AN/A6/30/2015232N/A3N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: AJ91の予測収益成長が 貯蓄率 ( 1.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: AJ91の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: AJ91の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: AJ91の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: AJ91の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: AJ91の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/29 01:21終値2026/05/29 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋DocCheck AG 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Declared Dividend • May 20Dividend increased to €1.00Dividend of €1.00 is 33% higher than last year. Ex-date: 29th May 2026 Payment date: 2nd June 2026 Dividend yield will be 6.6%, which is higher than the industry average of 0.9%. Sustainability & Growth Dividend is not adequately covered by earnings (95% earnings payout ratio) nor is it covered by cash flows (227% cash payout ratio). The dividend has increased by an average of 9.6% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 5.7% to bring the payout ratio under control. However, EPS has declined by 11% over the last 5 years so the company would need to reverse this trend.
お知らせ • Apr 17+ 1 more updateDocCheck AG, Annual General Meeting, May 28, 2026DocCheck AG, Annual General Meeting, May 28, 2026, at 09:30 W. Europe Standard Time.
お知らせ • Apr 16+ 1 more updateDocCheck AG announces Annual dividend, payable on June 02, 2025DocCheck AG announced Annual dividend of EUR 0.7500 per share payable on June 02, 2025, ex-date on May 29, 2025 and record date on May 30, 2025.
Valuation Update With 7 Day Price Move • Oct 01Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €8.40, the stock trades at a trailing P/E ratio of 17.6x. Average trailing P/E is 21x in the Healthcare Services industry in Europe. Total loss to shareholders of 59% over the past three years.
Reported Earnings • Sep 26First half 2024 earnings released: EPS: €0.37 (vs €0.34 in 1H 2023)First half 2024 results: EPS: €0.37 (up from €0.34 in 1H 2023). Revenue: €24.4m (down 6.8% from 1H 2023). Net income: €1.87m (up 10% from 1H 2023). Profit margin: 7.7% (up from 6.5% in 1H 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings.
New Risk • Sep 25New major risk - Revenue and earnings growthEarnings have declined by 4.3% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.3% per year over the past 5 years. Minor Risks Dividend is not well covered by earnings (104% payout ratio). Profit margins are more than 30% lower than last year (4.7% net profit margin). Market cap is less than US$100m (€37.8m market cap, or US$42.1m).
Upcoming Dividend • May 23Upcoming dividend of €0.50 per shareEligible shareholders must have bought the stock before 30 May 2024. Payment date: 03 June 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 5.5%. Within top quartile of German dividend payers (4.6%). Higher than average of industry peers (1.6%).
New Risk • Apr 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (€45.7m market cap, or US$48.6m).
Reported Earnings • Oct 05First half 2023 earnings released: EPS: €0.34 (vs €0.42 in 1H 2022)First half 2023 results: EPS: €0.34 (down from €0.42 in 1H 2022). Revenue: €26.2m (down 11% from 1H 2022). Net income: €1.70m (down 19% from 1H 2022). Profit margin: 6.5% (down from 7.1% in 1H 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.
New Risk • Jul 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (34% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (6.7% average weekly change). Market cap is less than US$100m (€53.4m market cap, or US$58.9m).
Upcoming Dividend • May 25Upcoming dividend of €0.75 per share at 5.8% yieldEligible shareholders must have bought the stock before 01 June 2023. Payment date: 05 June 2023. Payout ratio is a comfortable 60% but the company is not cash flow positive. Trailing yield: 5.8%. Within top quartile of German dividend payers (4.7%). Higher than average of industry peers (1.7%).
Valuation Update With 7 Day Price Move • May 22Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €13.50, the stock trades at a trailing P/E ratio of 10.5x. Average trailing P/E is 24x in the Healthcare Services industry in Germany. Total returns to shareholders of 52% over the past three years.
Buying Opportunity • Nov 12Now 25% undervaluedOver the last 90 days, the stock is up 5.1%. The fair value is estimated to be €21.98, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 35% over the last 3 years. Earnings per share has grown by 39%.
Valuation Update With 7 Day Price Move • Nov 05Investor sentiment improved over the past weekAfter last week's 19% share price gain to €14.80, the stock trades at a trailing P/E ratio of 6.7x. Average trailing P/E is 25x in the Healthcare Services industry in Germany. Total returns to shareholders of 76% over the past three years.
Upcoming Dividend • May 25Upcoming dividend of €1.00 per shareEligible shareholders must have bought the stock before 01 June 2022. Payment date: 03 June 2022. Payout ratio is a comfortable 44% and this is well supported by cash flows. Trailing yield: 5.3%. Within top quartile of German dividend payers (4.3%). Higher than average of industry peers (1.3%).
Buying Opportunity • May 21Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 28%. The fair value is estimated to be €22.93, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last 3 years. Earnings per share has grown by 61%.
Reported Earnings • Apr 16Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: EPS: €2.27 (up from €1.83 in FY 2020). Revenue: €86.4m (up 37% from FY 2020). Net income: €11.4m (up 24% from FY 2020). Profit margin: 13% (down from 15% in FY 2020). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 100%. Earnings per share (EPS) exceeded analyst estimates by 65%. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has only increased by 37% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • May 24Upcoming dividend of €1.00 per shareEligible shareholders must have bought the stock before 31 May 2021. Payment date: 02 June 2021. Trailing yield: 3.6%. Within top quartile of German dividend payers (3.2%). Higher than average of industry peers (1.1%).
Reported Earnings • Apr 18Full year 2020 earnings released: EPS €1.83 (vs €0.63 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €63.7m (up 97% from FY 2019). Net income: €9.20m (up 193% from FY 2019). Profit margin: 14% (up from 9.7% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €23.80, the stock trades at a trailing P/E ratio of 28.1x. Average trailing P/E is 51x in the Healthcare Services industry in Germany. Total returns to shareholders of 151% over the past three years.
Valuation Update With 7 Day Price Move • Feb 06Investor sentiment improved over the past weekAfter last week's 17% share price gain to €26.80, the stock is trading at a trailing P/E ratio of 31x, up from the previous P/E ratio of 26.6x. This compares to an average P/E of 42x in the Healthcare Services industry in Europe. Total returns to shareholders over the past three years are 183%.
Is New 90 Day High Low • Feb 05New 90-day high: €26.00The company is up 53% from its price of €17.00 on 06 November 2020. The German market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 3.0% over the same period.
Is New 90 Day High Low • Jan 07New 90-day high: €24.00The company is up 48% from its price of €16.20 on 09 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 5.0% over the same period.
Valuation Update With 7 Day Price Move • Dec 21Investor sentiment improved over the past weekAfter last week's 16% share price gain to €23.60, the stock is trading at a trailing P/E ratio of 27.1x, up from the previous P/E ratio of 23.4x. This compares to an average P/E of 44x in the Healthcare Services industry in Europe. Total returns to shareholders over the past three years are 160%.
Is New 90 Day High Low • Nov 11New 90-day high: €22.60The company is up 64% from its price of €13.80 on 13 August 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is flat over the same period.
Valuation Update With 7 Day Price Move • Nov 11Market bids up stock over the past weekAfter last week's 35% share price gain to €22.60, the stock is trading at a trailing P/E ratio of 20x, up from the previous P/E ratio of 14.8x. This compares to an average P/E of 44x in the Healthcare Services industry in Europe. Total returns to shareholders over the past three years are 156%.
Is New 90 Day High Low • Oct 08New 90-day high: €16.30The company is up 58% from its price of €10.30 on 10 July 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 8.0% over the same period.